IL316523A - Anti-ilt3 antibodies and use thereof - Google Patents

Anti-ilt3 antibodies and use thereof

Info

Publication number
IL316523A
IL316523A IL316523A IL31652324A IL316523A IL 316523 A IL316523 A IL 316523A IL 316523 A IL316523 A IL 316523A IL 31652324 A IL31652324 A IL 31652324A IL 316523 A IL316523 A IL 316523A
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
antibody
antigen binding
Prior art date
Application number
IL316523A
Other languages
English (en)
Hebrew (he)
Inventor
Tsuri Peretz
Ilana Mandel
Yoav Pizem
Liat Iancovici
Motti Hakim
Avidor Shulman
Yair Sapir
Tehila Ben-Moshe
Original Assignee
Biond Biologics Ltd
Tsuri Peretz
Ilana Mandel
Yoav Pizem
Liat Iancovici
Motti Hakim
Avidor Shulman
Yair Sapir
Ben Moshe Tehila
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biond Biologics Ltd, Tsuri Peretz, Ilana Mandel, Yoav Pizem, Liat Iancovici, Motti Hakim, Avidor Shulman, Yair Sapir, Ben Moshe Tehila filed Critical Biond Biologics Ltd
Publication of IL316523A publication Critical patent/IL316523A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL316523A 2022-04-25 2023-04-25 Anti-ilt3 antibodies and use thereof IL316523A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263334365P 2022-04-25 2022-04-25
PCT/IL2023/050426 WO2023209716A1 (en) 2022-04-25 2023-04-25 Anti-ilt3 antibodies and use thereof

Publications (1)

Publication Number Publication Date
IL316523A true IL316523A (en) 2024-12-01

Family

ID=86604937

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316523A IL316523A (en) 2022-04-25 2023-04-25 Anti-ilt3 antibodies and use thereof

Country Status (9)

Country Link
US (1) US20250277032A1 (https=)
EP (1) EP4514472A1 (https=)
JP (1) JP2025513588A (https=)
KR (1) KR20250025354A (https=)
CN (1) CN119487072A (https=)
AU (1) AU2023258644A1 (https=)
CA (1) CA3249138A1 (https=)
IL (1) IL316523A (https=)
WO (1) WO2023209716A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025062392A1 (en) * 2023-09-20 2025-03-27 Biond Biologics Ltd. Anti-ilt3 blockade combinations
WO2025141589A1 (en) 2023-12-31 2025-07-03 Biond Biologics Ltd. Treatment of cancer with anti-ilt3 antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1907001B1 (en) 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Ilt3 binding molecules and uses therefor
WO2013033734A1 (en) * 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand
CA2977544C (en) * 2015-03-06 2023-12-19 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
EP3538141A4 (en) 2016-11-10 2020-07-15 Merck Sharp & Dohme Corp. LIGAND ILT3
WO2018148494A1 (en) * 2017-02-09 2018-08-16 Bluefin Biomedicine, Inc. Anti-ilt3 antibodies and antibody drug conjugates
CN111712518B (zh) 2017-11-17 2025-03-25 默沙东有限责任公司 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途
CA3109366A1 (en) 2018-09-13 2020-03-19 The Board Of Regents Of The University Of Texas System Novel lilrb4 antibodies and uses thereof
JP2022522775A (ja) * 2019-03-01 2022-04-20 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｌｉｌｒｂ４結合抗体およびその使用方法
PH12022551462A1 (en) 2019-12-19 2023-11-13 Ngm Biopharmaceuticals Inc Ilt3-binding agents and methods of use thereof
AU2021236302A1 (en) * 2020-03-12 2022-10-20 Immune-Onc Therapeutics, Inc. Novel anti-LILRB4 antibodies and derivative products

Also Published As

Publication number Publication date
US20250277032A1 (en) 2025-09-04
CN119487072A (zh) 2025-02-18
JP2025513588A (ja) 2025-04-24
KR20250025354A (ko) 2025-02-21
WO2023209716A1 (en) 2023-11-02
EP4514472A1 (en) 2025-03-05
CA3249138A1 (en) 2023-11-02
AU2023258644A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
IL277354B1 (en) Methods and compositions for decreasing soluble immune receptor cd28
IL264970B1 (en) ANTI-TIM-3 antibodies and their use
IL250848B (en) Cancer cell-specific antibody, anti-cancer drug and cancer diagnosis method
US12503510B2 (en) Small shedding blocking agents
IL316523A (en) Anti-ilt3 antibodies and use thereof
IL295979A (en) Anti-cd36 antibodies and their use for cancer treatment
IL296514A (en) Bispecific antibody
IL297269A (en) Anti-flt3 antibodies and compositions
IL267340B2 (en) Anti-pcna monoclonal antibodies and use thereof
IL262588B1 (en) Humanized anti-basigin antibodies and the use thereof
IL292029A (en) Humanized antibodies against chemokin like receptor 1 and their therapeutic uses
IL293555A (en) Using mmp delay
IL296372A (en) Highly stable anti-shedding materials
JP7818747B2 (ja) 抗－ＣＤ３００ｃモノクローナル抗体及びその癌の予防または治療用バイオマーカー
IL311275A (en) Materials that block and/or screen c. 28 is enough
IL305818A (en) Multispecific stable compound and its use
JP2022525332A (ja) 免疫抑制の方法
IL307407A (en) Improved anti-HVEM antibodies and their use
WO2025062392A1 (en) Anti-ilt3 blockade combinations
US20230312732A1 (en) Ephb2 antibody and use thereof in combination therapy
WO2025215647A1 (en) Combination cancer treatment with staggered dosing
IL321979A (en) Freeze-drying process with controlled ice nucleation for bispecific molecules
IL323666A (en) Methods and compositions for treating autoimmune diseases
IL275943A (en) Changed CK and CH1 regions